Gilead Sciences, Inc. today announced three-year efficacy and safety results from two pivotal Phase 3 studies evaluating the once-daily single tablet regimen Stribild among treatment-naive patients with HIV-1 infection.
http://news.investors.com/newsfeed-business-wire/101613-141522704-gilead-s-single-tablet-hiv-regimen-stribild-demonstrates-durable-viral-suppression-through-three-years-of-therapy.aspx
http://news.investors.com/newsfeed-business-wire/101613-141522704-gilead-s-single-tablet-hiv-regimen-stribild-demonstrates-durable-viral-suppression-through-three-years-of-therapy.aspx
No comments:
Post a Comment